Autoimmune Profile Updates: Andrew McKeon, M.B., B.Ch., M.D.

(00:41)
 Before we get started talking about the panels, Dr. McKeon, could you provide a little background about yourself and your role here at Mayo Clinic?
 

(01:23)
 I think it's important for our audience to know that you're both seeing patients and working in the lab, which helps us at Mayo Clinic to have a real understanding of what patients and physicians need to get an accurate diagnosis. Is that right?

(02:09)
 I know there's a lot of panels that are impacted, Dr. McKeon. But could you give an overview, maybe talk about, in general, what changes are happening, so that our audience gets an understanding of what's going to change.

(06:47)
 You said that the primary antibodies that are being removed are calcium channel, striations. You said an alpha three antibody. Are those the primary ones that we're removing from most panels, or did I miss a couple?
 
 (07:24)
 So our audience will be able to see on our website, a chart, which panels are going to include which of these antibodies, but it sounds like a couple are being removed entirely. And then a couple of the other ones — the alpha three, and of course PQ, and Lambert Eaton, and movement disorder — are going to stick around because they're specific to that phenotype, but they're being removed from the other panels. Correct?

(08:29)
 Why did we decide to remove them now? And are you worried about anything in the future — the way our panels will be designed when these antibodies are removed?

(11:27)
 So can you talk about ways that Mayo Clinic is partnering and available to help physicians pick the right test, to make sure that they're getting the antibodies needed and in the right context?

(14:30)
 To wrap up Dr. McKeon, can you just share with our listeners what you're most excited about — or maybe the key takeaway for physicians that have used Mayo's testing and maybe are apprehensive about these changes, or maybe someone that hasn't ordered Mayo Clinic's testing before, but these changes could be an opening for them to utilize Mayo Clinic's resources.

(15:39)
 Is there anything you want to add about antibodies on the horizon that will be added to our panels, Dr. McKeon?